ClinicalTrials.gg
RecruitingNCT07085975Updated Aug 29, 2025

The Safety, Feasibility, and Repeatability of Inhaled ATP Cough Challenges

A Phase 1 interventional study of Adenosine 5'-triphosphate in Chronic Cough (CC) and Asthma, sponsored by McMaster University. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-29.

Sponsored by McMaster University · Phase 1, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Chronic Cough with a site in Canada — 7 open to participants now, 8 under way, none of them phase 3. Chronic Cough · Canada.

Planned enrollment
17th of 18
33 · median 122
Started
2025
with 2 others
Phase 1
Only one
of the 22
Registered
20th of 22
by date
Lead sponsor
7 of 22
McMaster University

Among the 22 studies in Chronic Cough with a site in Canada, this one is the 17th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2025, is the only one in phase 1, and was the 20th registered.

Chronic Cough

142 studies on the registry are indexed under Chronic Cough; 38 are open to participants now.

Browse Chronic Cough studies →

Open to participants now

7 of the 22 studies in Chronic Cough with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 12 (40%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Chronic Cough with a site in Canada, or all of them as a file.
02

Study summary

The inhalation of adenosine 5'-triphosphate (ATP) to evoke cough (ATP cough challenge) is becoming increasingly used as a tool to measure cough hypersensitivity in patients with chronic cough. However, the safety, feasibility, and repeatability of this procedure is not widely known. In this study, we will perform ATP cough challenges in healthy individuals and in patients with mild asthma and chronic cough to better understand the safety, feasibility, and repeatability of these challenges. Such information will guide the future conduct of ATP cough challenges to measure cough hypersensitivity and identify patients who may better respond to ATP-blocking therapies.

03

Conditions studied

  • Chronic Cough (CC)
  • Asthma

Keywords

  • adenosine triphosphate
  • chronic cough
  • asthma
  • cough hypersensitivity syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Phase 1: Healthy individuals

Inclusion Criteria:

Eligible participants in Phase 1 will include healthy adults (≥18 years old) with:

  1. Normal spirometry; and
  2. No current or past medical history of chronic cough or other respiratory diseases.

Exclusion Criteria:

We will exclude healthy individuals meeting the following:

(1) Are a current or former smoker with a >5 pack-year history and abstinence ≤6 months;

  1. Unable to perform acceptable and reproducible spirometry;
  2. Have unresolved symptoms of upper respiratory tract infection within 6 weeks prior to the first study visit;
  3. Have had a lower respiratory tract infection or pneumonia within 6 weeks prior to the first study visit;
  4. Presence of other primary pulmonary disorders, including pulmonary embolism, pulmonary hypertension, lung cancer, cystic fibrosis, radiologically-proven emphysema, severe bronchiectasis, or severe interstitial lung disease; or
  5. History of psychiatric illness, drug, or alcohol abuse that could interfere with participation in the study.
  6. History of clinically-significant cardiovascular disease, including coronary artery disease, aortic aneurysm, or stroke in the last 3 months;
  7. Those with serious medical conditions or those who are not on stable medication(s) for their condition(s);
  8. Those with immune system disorders, severe allergy, or on allergy-specific immunotherapy;
  9. Any other condition, that, in the opinion of the qualified investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant;
  10. Pregnant or breastfeeding;
  11. Women of who:

    1. Do not agree to use a medically approved method of for the duration of the study. All hormonal birth control must have been in use for a minimum of 3 months. Acceptable methods of birth control include oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant, double-barrier method, intrauterine devices, non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s), vasectomy of partner at least 6 months prior to screening. Females who are not of child-bearing potential will be defined as females who have undergone a sterilization procedure (e.g., hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been for at least 1 year prior to screening.

Phase 2: Patients with RCC/UCC and mild- naïve asthma

Inclusion Criteria:

Eligible participants will include adults (≥18 years old) with:

  1. RCC/UCC for >1 year, demonstrated by a normal chest radiograph and no airflow obstruction (/FVC>0.7/LLN) with either:

    1. Insufficient improvement in cough despite treatment targeting any underlying condition(s) contributing to the cough (RCC); or
    2. Cough for which an underlying cause has not been determined despite thorough investigation (UCC).
  2. Mild steroid-naïve asthma who demonstrate evidence of a positive screening methacholine (PC20\<16 mg/mL); symptoms of cough, shortness of breath, chest tightness, and wheeze, that, in the opinion of the qualified investigator, are well-controlled; and those have not used inhaled or oral corticosteroids for the past month.

Exclusion Criteria:

Cohort-specific exclusion criteria include the following:

For the RCC/UCC cohort:

(1) Current smoker or ex-smoker with ≥20 pack-year history and abstinence ≤6 months;

For the mild steroid-naïve asthma cohort:

  1. Current smoker or ex-smoker with ≥20 pack-year history and abstinence ≤6 months;
  2. History or exacerbation or uncontrolled symptoms within the last month prior to the first study visit; and
  3. Use of inhaled or oral corticosteroids within the last month prior to the first study visit.

We will exclude participants meeting any of the following criteria from the study:

  1. Unable to perform acceptable and reproducible spirometry;
  2. Unresolved symptoms of upper respiratory tract infection within 6 weeks prior to the first study visit;
  3. Lower respiratory tract infection or pneumonia within 6 weeks prior to the first study visit;
  4. Presence of other primary pulmonary disorders, including pulmonary embolism, pulmonary hypertension, lung cancer, cystic fibrosis, radiologically-proven emphysema, severe bronchiectasis, or severe interstitial lung disease;
  5. History of psychiatric illness, drug, or alcohol abuse that could interfere with participation in the study;
  6. History of clinically-significant cardiovascular disease, including coronary artery disease, aortic aneurysm, or stroke in the last 3 months;
  7. Those with serious medical conditions or those who are not on stable medication(s) for their condition(s);
  8. Those with immune system disorders, severe allergy, or on allergy-specific immunotherapy;
  9. Any other condition, that, in the opinion of the qualified investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant;
  10. Pregnant or breastfeeding;
  11. Female participants of child-bearing potential who:

    1. Do not agree to use a medically approved method of birth control for the duration of the study;
    2. Have not been using hormonal birth control for a minimum of 3 months prior to screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Adenosine 5'triphosphate

    Drug: Adenosine 5'-triphosphate

Interventions

06

What researchers measure

Primary outcomes

  1. The mean %FEV1 change from baseline at incremental doses of ATP

    Time frame: Until the end of the ATP cough challenge

  2. Symptoms of wheeze measured on the mBorg scale at incremental doses of ATP

    Time frame: Until the end of the ATP cough challenge

  3. Symptoms of chest tightness measured on the mBorg scale at incremental doses of ATP

    Time frame: Until the end of the ATP cough challenge

  4. Symptoms of shortness of breath measured on the mBorg scale at incremental doses of ATP

    Time frame: Until the end of the ATP cough challenge

  5. The mean change in oxygen saturations (SpO2) from baseline at incremental doses of ATP

    Time frame: Until the end of the ATP cough challenge

  6. The intra-class correlation of measures obtained from repeat ATP cough challenges

    Time frame: Baseline to 1 week

  7. The frequency of adverse events

    Time frame: Baseline to 1 week

  8. Total maximum number of evoked coughs (Emax) by any dose of ATP

    Time frame: Until the end of the ATP cough challenge

  9. The dose of ATP that induces at least 50% of the maximal cough response (ED50)

    Time frame: Until the end of the ATP cough challenge

  10. The dose of ATP that induces at least 5 coughs (C5)

    Time frame: Until the end of the ATP cough challenge

  11. The dose of ATP that induces at least 2 coughs (C2)

    Time frame: Until the end of the ATP cough challenge

07

Study locations

1 of 1 sites recruiting
  • Respiratory Research Lab
    Hamilton, Ontario L8N 3Z5, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Aug 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2025
First posted
Jul 25, 2025
StartActual
Aug 5, 2025
Primary completionEst.
Aug 1, 2026
CompletionEst.
Oct 1, 2026
Last update
Aug 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07085975
Responsible party
Sponsor
First posted
Jul 25, 2025
Start date
Aug 5, 2025
Primary completion
Aug 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Aug 29, 2025

Study contacts

Imran Satia, MD PhD
Contact
satiai@mcmaster.ca
905-525-2100 ext. 76228

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adenosine Triphosphate

Start the discussion